Affentranger Associates

Affentranger Associates is a venture capital firm established in 2002 and located in Zurich, Switzerland. The firm specializes in value creation through hands-on management, focusing on sustainable long-term returns by investing in companies undergoing transitions. Affentranger Associates primarily targets investments in the technology and industrial sectors, aiming to combine capital and labor investments to foster growth and development within these industries.

Anton Affentranger

Founder and Senior Partner

6 past transactions

InflaRx

Series A in 2009
InflaRx is a clinical-stage biopharmaceutical company based in Jena, Germany, specializing in the development of therapeutics for acute and chronic inflammation. Founded in December 2017, the company leverages proprietary anti-C5a/C5aR technology to create first-in-class inhibitors targeting the complement activation factor C5a and its receptor, C5aR. C5a is a key inflammatory mediator implicated in various autoimmune and inflammatory diseases. InflaRx’s lead product candidate, vilobelimab, is a novel monoclonal antibody designed for intravenous delivery. It selectively binds to free C5a and has shown disease-modifying clinical activity and tolerability across several clinical trials. The company is composed of a team of internationally recognized researchers and clinicians dedicated to translating their expertise into innovative therapeutic solutions.

InflaRx

Seed Round in 2008
InflaRx is a clinical-stage biopharmaceutical company based in Jena, Germany, specializing in the development of therapeutics for acute and chronic inflammation. Founded in December 2017, the company leverages proprietary anti-C5a/C5aR technology to create first-in-class inhibitors targeting the complement activation factor C5a and its receptor, C5aR. C5a is a key inflammatory mediator implicated in various autoimmune and inflammatory diseases. InflaRx’s lead product candidate, vilobelimab, is a novel monoclonal antibody designed for intravenous delivery. It selectively binds to free C5a and has shown disease-modifying clinical activity and tolerability across several clinical trials. The company is composed of a team of internationally recognized researchers and clinicians dedicated to translating their expertise into innovative therapeutic solutions.

Selfrag

Funding Round in 2007
Selfrag AG is a Swiss company founded in 2007, specializing in the development and marketing of high voltage electric pulse generators and electric pulse disaggregation (EPD) systems. The company focuses on selective fragmentation of solid materials, offering solutions that reduce energy consumption compared to traditional crushing and grinding methods. Its product lineup includes laboratory systems for selective fragmentation, a rod crusher designed for fragmenting mono and poly-crystalline silicon with minimal contamination, and Scoria, a modular production system for transporting and fragmenting bulky materials like rock and concrete. Selfrag serves a diverse range of industries, including geosciences, recycling, and mining, and has established over 40 installations worldwide. The company aims to provide advanced processing solutions that enhance material recovery and sustainability in the mineral processing sector.

SIRS-Lab

Venture Round in 2006
SIRS-Lab is a privately held diagnostic company developing unique and innovative products to identify and monitor life-threatening infections, one of the major causes of death in hospitals across the world. SIRS-Lab's vision is to support clinicians in their bedside decisions by providing them with fast and reliable high-performance point of care systems and thus, to improve therapeutic impact and reduce the mortality rate of patients. Founded in 2000 by S. Russwurm, K. Reinhart, E. Straube and H.-P. Saluz, SIRS-Lab employs today 45 people. The company currently commercializes VYOO, a molecular diagnostic test for the rapid identification of sepsis causing bacteria and fungi. Sepsis is one of the major causes of death in hospitals.

Dunes Technologies

Venture Round in 2006
Dunes Technologies is a software development company based in Vaud, Switzerland, established in 2000. The company specializes in process automation and system management solutions tailored for virtual service and virtual desktop environments. Dunes Technologies provides a comprehensive suite of cost-effective tools designed to efficiently manage virtual IT infrastructures. By leveraging automation, the company enhances IT operations performance and maximizes the benefits of virtualization. Its proactive service mediation platform supports the development of S-Ops products, which manage application-based services throughout their entire operational life cycle.

Dartfish

Venture Round in 2002
Dartfish SA is a company that specializes in video solutions aimed at enhancing performance across various sectors, including sports, education, healthcare, and industry. Founded in 1999 and headquartered in Fribourg, Switzerland, Dartfish offers a range of products designed for capturing, analyzing, and sharing video content. Key offerings include myDartfish, a personal workspace for skill analysis; myDartfish Express, which identifies areas for athlete improvement; and myDartfish Smart Cloud, a secure platform for storing and sharing video assets. Additionally, Dartfish provides ProSuite for automatic tracking of video annotations, Dartfish Connect for combining video with notes, and tools for live video analysis. The company also operates Dartfish.tv, a video sharing site that enhances video content with features like special effects. With a global presence, including offices in the United States, Europe, Asia, and Australia, Dartfish is recognized for its innovative contributions to video technology and has received multiple awards for its work in the field.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.